Cargando…

Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance

Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are the preferential options for advanced non-small cell lung cancer (NSCLC) patients harboring EGFR mutations. Osimertinib is a potent irreversible third-generation EGFR-TKI targeting EGFR mutations but has little effect on wil...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Kai, Xie, Fachao, Wang, Fang, Fu, Liwu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9733018/ https://www.ncbi.nlm.nih.gov/pubmed/36482474 http://dx.doi.org/10.1186/s13045-022-01391-4

Ejemplares similares

Intercellular transfer of exosomal wild type EGFR triggers osimertinib resistance in non-small cell lung cancer
por: Wu, Shaocong, et al.
Publicado: (2021)

Resistance mechanisms to osimertinib in EGFR-mutated non-small cell lung cancer
por: Leonetti, Alessandro, et al.
Publicado: (2019)

Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
por: Mazza, Valentina, et al.
Publicado: (2017)

EGFR exon 20 insertion mutations and response to osimertinib in non-small-cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2019)

Brigatinib combined with anti-EGFR antibody overcomes osimertinib resistance in EGFR-mutated non-small-cell lung cancer
por: Uchibori, Ken, et al.
Publicado: (2017)

Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance
por: Araki, Taisuke, et al.
Publicado: (2023)

Osimertinib and pterostilbene in EGFR-mutation-positive non-small cell lung cancer (NSCLC)
por: Bracht, Jillian Wilhelmina Paulina, et al.
Publicado: (2019)

Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer
por: Li, Yufeng, et al.
Publicado: (2023)

Rare Mechanism of Acquired Resistance to Osimertinib in Korean Patients with EGFR-mutated Non-small Cell Lung Cancer
por: Lee, Jiyun, et al.
Publicado: (2019)

Acquired Resistance to Osimertinib in EGFR-Mutated Non-Small Cell Lung Cancer: How Do We Overcome It?
por: Bertoli, Elisa, et al.
Publicado: (2022)

EGFR mutation tracking predicts survival in advanced EGFR-mutated non-small cell lung cancer patients treated with osimertinib
por: Buder, Anna, et al.
Publicado: (2020)

Cardiac Adverse Events in EGFR-Mutated Non-Small Cell Lung Cancer Treated With Osimertinib
por: Kunimasa, Kei, et al.
Publicado: (2020)

Resistance Profile of Osimertinib in Pre-treated Patients With EGFR T790M-Mutated Non-small Cell Lung Cancer
por: Fernandes, Maria Gabriela O., et al.
Publicado: (2021)

Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies
por: Di Noia, V., et al.
Publicado: (2021)

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer
por: Yan, Dan, et al.
Publicado: (2022)

Pancytopenia During Osimertinib Treatment in a Patient with EGFR-Mutated Non-Small Cell Lung Cancer
por: Di Marino, Pietro, et al.
Publicado: (2022)

Adjuvant osimertinib for resected EGFR-mutated non-small cell lung cancer: a game-changer?
por: Patel, Shruti R., et al.
Publicado: (2023)

Beneficial Effect of Osimertinib Readministration in Non-small-cell Lung Cancer Harboring an Epidermal Growth Factor Receptor (EGFR) Mutation with a History of Acquired Resistance to Osimertinib
por: Makimoto, Go, et al.
Publicado: (2019)

HER2-D16 oncogenic driver mutation confers osimertinib resistance in EGFR mutation-positive non-small cell lung cancer
por: Yamaoka, Toshimitsu, et al.
Publicado: (2020)

Durable Response to Combined Osimertinib and Pralsetinib Treatment for Osimertinib Resistance Due to Novel Intergenic ANK3-RET Fusion in EGFR-Mutated Non–Small-Cell Lung Cancer
por: Urbanska, Edyta M., et al.
Publicado: (2022)

ALK rearrangements as mechanisms of acquired resistance to osimertinib in EGFR mutant non‐small cell lung cancer
por: Hou, Helei, et al.
Publicado: (2021)

Acquired BRAF gene fusions in Osimertinib resistant EGFR-mutant non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2023)

Clinical Characteristics of Osimertinib Responder in Non-Small Cell Lung Cancer Patients with EGFR-T790M Mutation
por: Yoshimura, Akihiro, et al.
Publicado: (2019)

Dose escalation of osimertinib for intracranial progression in EGFR mutated non-small-cell lung cancer with brain metastases
por: Goldstein, Iris M, et al.
Publicado: (2020)

Negative impact of malignant effusion on osimertinib treatment for non-small cell lung cancer harboring EGFR mutation
por: Kawamura, Takahisa, et al.
Publicado: (2019)

Osimertinib as induction therapy for oligometastatic non-small cell lung cancer with EGFR mutation: a case report
por: Wu, Han, et al.
Publicado: (2022)

Cost‐effectiveness of osimertinib versus placebo in resected EGFR‐mutated non‐small cell lung cancer in China
por: Zhou, Xiwen, et al.
Publicado: (2022)

Notch pathway regulates osimertinib drug‐tolerant persistence in EGFR ‐mutated non–small‐cell lung cancer
por: Takahashi, Hirofumi, et al.
Publicado: (2022)

Dysregulated expression of microRNA involved in resistance to osimertinib in EGFR mutant non-small cell lung cancer cells
por: Zhang, Dianbao, et al.
Publicado: (2023)

Author Correction: Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer
por: Chmielecki, Juliann, et al.
Publicado: (2023)

Potential treatment strategy for the rare osimertinib resistant mutation EGFR L718Q
por: Song, Yang, et al.
Publicado: (2020)

Potential treatment strategy for the rare osimertinib resistant EGFR L718Q mutation
por: Kawase, Akikazu, et al.
Publicado: (2022)

Afatinib and osimertinib in lung adenocarcinoma harbored EGFR T751_I759delinsS mutation: A case report
por: Fang, Yueh‐Fu, et al.
Publicado: (2021)

ADAURA: The Splash of Osimertinib in Adjuvant EGFR-Mutant Non-small Cell Lung Cancer
por: Ortega-Franco, Ana, et al.
Publicado: (2022)

EGFR T790M relative mutation purity predicts osimertinib treatment efficacy in non-small cell lung cancer patients
por: Zheng, Qiufan, et al.
Publicado: (2020)

Inhibition of PLK1 Destabilizes EGFR and Sensitizes EGFR-Mutated Lung Cancer Cells to Small Molecule Inhibitor Osimertinib
por: Eggermont, Carolien, et al.
Publicado: (2023)

Combatting acquired resistance to osimertinib in EGFR-mutant lung cancer
por: Lee, Jiyun, et al.
Publicado: (2022)

The MEK/ERK/miR-21 Signaling Is Critical in Osimertinib Resistance in EGFR-Mutant Non-Small Cell Lung Cancer Cells
por: Huang, Wen-Chien, et al.
Publicado: (2021)

First- and Second-Generation EGFR-TKIs Are All Replaced to Osimertinib in Chemo-Naive EGFR Mutation-Positive Non-Small Cell Lung Cancer?
por: Takeda, Masayuki, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_v2p6iji2rroruu4a2n8jeea4lt